Customers Tout Medrio’s EDC Software as Ideal Solution for Phase 1 Studies

Medrio’s eClinical Software praised by customers for being ideal for Phase 1 studies.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This

Medrio logo

The ease of use and setup are superior to the competition.

San Francisco, CA (PRWEB) December 31, 2013

Medrio, a leading Software as a Service (SaaS) provider of electronic data capture (EDC) software is lauded by customers for providing an advanced EDC solution that is ideal for Phase 1 clinical studies. Medrio’s affordable EDC software enables customers to build and deploy studies within days and includes features perfect for Phase 1 studies. These features include multiple subject data entry to enhance workflows and iPad® support for on-site data entry.

“I’m very impressed with the layout in Medrio,” said Diana Reist, Senior Records Specialist at Jasper Clinic, a Phase 1 clinic specializing in complex clinical pharmacology studies. “Data entry is very easily accomplished within the system. It is easy to add new subjects and to search for subjects already enrolled.”

“The addition of iPad® support will help our monitors greatly in the field,” said Ashleigh Willson, Clinical Data Manager at Heartflow.

“Medrio addresses the needs of Phase I studies by adapting to the unique workflows for intuitive navigation and superior data entry,” said Scott Weidley, Vice President of Sales and Marketing at Medrio. “We work diligently to provide exceptional features and functionality that best fit our customer needs.”

About Medrio, Inc.
Medrio offers an integrated eClinical Software as a Service (SaaS) platform with a fully hosted Electronic Data Capture (EDC) system that drastically reduces study timelines and costs by putting study managers in control of their studies. By enabling studies to be built completely online without the need for any custom development, Medrio eClinical software allows studies to be ready in days instead of weeks. Medrio has been used successfully in Phase I-IV trials, registries, and other clinical studies by a number of leading contract research organizations (CROs), as well as biopharmaceutical and device companies.Founded in 2005, Medrio is headquartered in the San Francisco Bay Area. For more information visit http://www.medrio.com.


Contact

  • Alexandra Allison
    Medrio
    +1 (415) 963-3700 Ext: 241
    Email